Evidence map›Paper›PMID 40261593›Full record

ArticleMedical oncology (Northwood, London, England)2025

Mechanism of Dahuang-Dangshen drug pairs in the treatment of HCC based on network pharmacology, bioinformatics, molecular docking and experimental verification.

Pan Yu, Shuhui Feng, Weifan Wang, Weiya Cao, Yongchang Cao

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pan YuThe First Affiliated Hospital of Anhui, University of Science and Technology, Huainan, 232001, China. 2020035@aust.edu.cn.ORCID http://orcid.org/0000-0002-7721-829X
Shuhui FengCollege of Public Health, Anhui University of Science and Technology, Hefei, 230000, China.
Weifan WangJiangsu Co-Innovation Center for Efficient Processing and Utilization of Forest Products, College of Chemical Engineering, Nanjing Forestry University, Nanjing, 210037, China.
Weiya CaoCollege of Public Health, Anhui University of Science and Technology, Hefei, 230000, China.
Yongchang CaoCollege of Public Health, Anhui University of Science and Technology, Hefei, 230000, China.

Funding

Anhui Provincial Natural Science Foundation 2108085QH381Joint Research Center of Occupational Medicine and Health, Institute of Grand Health, Hefei Comprehensive National Science Center (Anhui University of Science and Technology) OMH-2023-14Medical Special Cultivation Project of Anhui University of Science and Technology YZ2023H1B005Natural Science Research Project of Anhui Educational Committee KJ2021A0436Scientific Research Foundation for High-level Talents of Anhui University of Science and Technology 2022yjrc69
6 · The paper itself

Abstract

The anti-hepatocellular carcinoma (HCC) effect of the active ingredients of natural Chinese herbal medicine has become a hot topic at home and abroad. A list of studies evidence the therapeutic efficacy of Dahuang (DH) or Dangshen (DS) against HCC, but the combination effect of DH and DS in HCC treatment is rarely reported and the molecular mechanism of the drug pairs is not yet clear. Therefore, in this study, the combined effects and potential mechanisms of DH and DS drug pairs were investigated through network pharmacology, bioinformatics, molecular docking, and a series of pharmacological experiments, including the MTT assay, clone formation, wound healing, JC-1 staining, and western blotting. In total, 140 intersection targets between the DH-DS drug pairs and HCC were identified. In the PPI network, the top ten hub targets with the highest node connection values were VEGFA, AKT, CTNNB1, EGFR, TNF, CASP3, HRAS, SRC, JUN, and ESR1. GO functional and KEGG pathway enrichment analysis involved 289 biological processes, 33 cellular components, 57 molecular functions, and 143 signaling pathways. Bioinformatic analysis indicated that EGFR and AKT were promising candidate genes that can serve as diagnostic and prognostic biomarkers for HCC. β-sitosterol from the DH drug and luteolin from the DS drug were found as promising small molecules for HCC. The experimental results showed that the combination of β-sitosterol and luteolin was more potent in suppressing cell proliferation, migration and inducing cell apoptosis when compared to β-sitosterol or luteolin alone. The western blot and molecular docking studies demonstrated that the potential mechanism may be related to the EGFR/AKT signaling pathway. In summary, the combination of DH and DS may resist cell proliferation, migration and promote apoptosis activity through the EGFR/AKT signaling pathway, which provides new insights for further exploring plant extract treatment for HCC.

Indexed as

Carcinoma, HepatocellularDrugs, Chinese HerbalLiver NeoplasmsApoptosisCell Line, TumorCell MovementCell ProliferationComputational BiologyErbB ReceptorsHumansMolecular Docking SimulationNetwork PharmacologyProtein Interaction MapsSignal TransductionDrugs, Chinese HerbalErbB ReceptorsBioinformaticsDahuang–DangshenEGFR/AKT signaling pathwayHCCMolecular dockingNetwork pharmacology

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.